Acne News

Clascoterone cream 1% may be a safe and effective alternative to traditional medications for the long-term treatment of acne vulgaris in patients aged 12 years and older, according to a phase 3 extension trial.

Post-acne scarring should be treated as a distinct condition from acne vulgaris and deserves a comprehensive and unique clinical approach, according to a study.

A combination of microencapsulated benzoyl peroxide and microencapsulated tretinoin significantly reduced inflammatory and noninflammatory lesions in patients with moderate to severe acne vulgaris, according to two phase 3 trials.

Patients with rosacea, alopecia areata, psoriasis or atopic dermatitis all face an elevated risk for cardiovascular disease, according to a study.

Acne is one of the most common skin disorders that affects a wide range of individuals but specifically targets those aged 12 to 24 years. In fact, 85% of people in this age range experience acne, according to Yale Medicine.

In new pharmacokinetic analyses, patients treated with TMB-001 0.05% ointment for congenital ichthyosis experienced minimal systemic absorption of isotretinoin or its major metabolites, Timber Pharmaceuticals announced in a press release.

While some adolescents treated with isotretinoin for moderate to severe acne vulgaris reported mood-changes, a majority experienced improvement in symptoms and completed treatment, according to a study.

A new gel for treating acne vulgaris is set to undergo FDA review with the agency’s acceptance of a new drug application for investigational IDP-126, according to a press release from Bausch Health.

The fixed-combination IDP-126 showed promising results as the first triple-combination product for the treatment of acne in patients aged as young as 9 years, according to a study.

NEW ORLEANS — Trifarotene monotherapy, a convenient topical treatment, offers clinical efficacy, safety and tolerability in adolescents with moderate facial and truncal acne vulgaris, according to a poster presented here.